Declaration of Interests
AL is an employee of the University of Cambridge, and an ex-employee of the Australian National University, the University of Washington, the VIB, the Babraham Institute and the University of Leuven. AL is affiliated with St Catharine'e College and was previously affiliated with Churchill College. The spouse of AL is an ex-employee of UCB and B&D and a current employee of Fight Bladder Cancer.
Patents and provisional patents
Inventor on EP131670416 ‘Mcl-1 as critical regulator of Foxp3+ regulatory T cell survival, and use thereof to treat severe immune disorders’.
Inventor on EP14173514.2 ‘Methods for selective cell ablation’.
Inventor on EP16195675.0 ‘Means and methods to influence the immune response’.
Inventor on PCT/GB2020/052148 ‘Manipulation of local IL2 expression in order to treat neuroinflammatory disease’
Inventor on GB2118073.2 'Manipulation of local IL2 expression in order to treat neurological ageing'
Inventor on GB2202628.0' Manipulation of local IL2 expression in order to treat ALS'
Inventor on GB2103327.9 'Manipulation of local IL2 expression in order to treat respiratory disease’
Inventor on GB 2202898.9 'Manipulation of local Manf expression in order to treat diabetes’
Under the institutional return-to-inventor schemes, commercialisation of these patents would provide a financial benefit to the inventors.
Paid travel
2018, paid travel to Biogen (Boston, US).
2023, paid travel to Merck (Boston, US).
Paid consulting
2012, 2018, consulting for Gerson Lehrman Group.
2020, consulting for Immune Regulation.
2020-2022, consulting for Sofinnova.
2021-current, Scientific Advisory Board member for Imcyse.
2021, Scientific Advisory Board for Sangamo
2023-current, Scientific Advisory Board for Enhanc3D
Shares and managed funds
No shares ever directly held in a publicly-listed company in the life sciences sector. No sector-specific managed fund / pension fund direction given.
Contract research and collaborative industry research
The laboratory has performed contract research for:
2016-2017, Complix
2016, Noxxon
2015, Complix
Contract research makes up less than 1% of the laboratory budget
The laboratory has performed collaborative industrial research with:
2017-2020, Janssen
2017-2018, Novartis
2020, BD Biosciences
2021, Reflection Therapeutics
2022, Cell Guidance Systems
All collaborative research with industry funding is entered into on the condition of full publication rights given to the laboratory, without right of publication veto given to the industrial funder
Spin-off company formation
AL is Director and Founder of Aila Biotech Ltd, a pre-Seed spin-off company from the Babraham Institute and University of Cambridge with a time-limited exclusive option to commercialise PCT/GB2020/052148, GB2118073.2, GB2202628.0, GB2103327.9 and GB2202898.9
Last updated February 2024